Concepedia

Bart Lutterbach

BL

29

Publications

4.4K

Citations

26

H-Index

1994

Active since

Affiliations

Vanderbilt University(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

St. Jude Children's Research Hospital

Johns Hopkins University

Brigham and Women's Hospital

Bart Lutterbach is an author at Vanderbilt University specializing in medicine, cell biology, and cell signaling.

Top concepts

Publications per year

1994–2020

29

Publications

29

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

Erick J. Morris, Sharda Jha, Clifford R. Restaino et al. · Cancer Discovery · 2013 · 673 citations · Full text

, , +20

ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors

Bart Lutterbach, Jennifer J. Westendorf, Bryan Linggi et al. · Molecular and Cellular Biology · 1998 · 439 citations · Full text

ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain

Joseph M. Amann, John Nip, David K. Strom et al. · Molecular and Cellular Biology · 2001 · 339 citations · Full text

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and Survival

Bart Lutterbach, Qinwen Zeng, Lenora J. Davis et al. · Cancer Research · 2007 · 316 citations

<i>FGFR2</i> -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora J. Davis, Julie Gorenstein et al. · Cancer Research · 2008 · 264 citations

Rows per page

1–5 of 29